论文部分内容阅读
目的以2型糖尿病合并高血压病患者为研究对象,探讨糖化血红蛋白(Hb A1C)与血压变异性的相关性。方法将180例糖尿病合并高血压患者根据Hb A1C水平分为:正常组(Hb A1C≤6.0%,n=62);正常高值组(6.0%6.0%,n=60),测定患者Hb A1C和血压变异性,之后分析其相关性。结果 2型糖尿病合并高血压病患者血压变异性指标(24h SBPSD、24h SBPCV、d SBPSD、d SBPCV、n SBPSD、n SBPCV)与Hb A1C具有明显的相关性。结论对于2型糖尿病合并高血压病患者,在降压治疗的同时,通过积极控制血糖水平,可降低其血压变异性,从而降低周围血管等靶器官损害和心血管事件。
Objective To investigate the relationship between glycosylated hemoglobin (Hb A1C) and blood pressure variability in type 2 diabetic patients with hypertension. Methods According to the level of Hb A1C in 180 cases of diabetic patients with hypertension, the patients in the normal group (Hb A1C≤6.0%, n = 62), the normal high-value group (6.0% 6.0%, n = 60), Hb A1C and blood pressure variability were measured in patients with Hb A1C. The correlation was then analyzed. Results The indexes of blood pressure variability (24h SBPSD, 24h SBPCV, d SBPSD, d SBPCV, n SBPSD, n SBPCV) in type 2 diabetic patients with hypertension were significantly correlated with Hb A1C. Conclusions In patients with type 2 diabetes mellitus and hypertension, blood pressure variability can be reduced by actively controlling blood glucose levels while reducing blood pressure, thereby reducing the target organ damage and cardiovascular events in peripheral blood vessels.